Suggestions
Mark Gorelick, PhD
Seasoned health technology executive with 15+ years of experience in product management with a core expertise in building digital health ecosystems.
Mark Gorelick, PhD, is a meticulous and diligent professional with a credible history in end-to-end product development for hardware and software products across dynamic business environments. He has a diverse background working on projects for B2B and D2C markets, including mobile and cloud-based platforms. Mark is known for his resourcefulness and results-driven approach, offering expertise as a health technology professional, biomedical specialist, product developer, researcher, and educator. His experience includes directing large-scale industry projects focused on digital technology and health outcomes, utilizing scientific knowledge to drive strategic decisions for enterprises. As a biomedical researcher and educator, Mark has developed innovative software and hardware products for various industries, specializing in biometric wearables and algorithm development. His leadership skills and ability to influence teams have been instrumental in achieving high performance levels and nurturing relationships with clients and colleagues to meet organizational goals.
Highlights
A nice summary article from Scientific American - The Biggest Health and Medicine Stories of 2023
Quick summary:
🌐 Advancements in Weight-Loss Drugs: New generation drugs like Wegovy and Ozempic show potential benefits beyond weight loss, including heart attack and stroke risk reduction.
🩹 End of COVID Public Health Emergency: The federal public health emergency for COVID concluded on May 11, transitioning to long-term management despite the ongoing circulation of the virus.
🐷 Progress in Xenotransplants: Scientists made strides in xenotransplants, with the second-ever transplant of a genetically engineered pig heart and successful experiments in other animals.
💉 Approval of RSV Vaccines: Safe and effective vaccines for respiratory syncytial virus (RSV) were approved by the FDA, protecting pregnant individuals, older adults, and children.
🧬 Milestone in CRISPR Gene Editing: The FDA approved the first CRISPR-based treatment, exa-cel, for sickle cell disease, deactivating a faulty gene and preventing symptoms in clinical trials.
🩺 Insights into Long COVID: Long COVID, resembling a neurological disease, was better understood, showing cognitive and autonomic nervous system-related symptoms.
🤖 Integration of AI in Medicine: Chat-based AI systems, including ChatGPT, entered medicine, offering potential in diagnosis and therapy, though caution is advised.
👁️ Groundbreaking Face and Eye Transplant: The first partial face and whole-eye transplant provided hope for restoring appearance and function in individuals with traumatic eye injuries.
#HealthInnovation #MedicalAdvancements #ScienceBreakthroughs #HealthTech #MedicalResearch
Health experts are redefining cardiovascular disease (CVD) risk, prevention, and management based on a new American Heart Association advisory. They have identified strong connections between CVD, kidney disease, Type 2 diabetes, and obesity, proposing the term "cardiovascular-kidney-metabolic (CKM) syndrome." The advisory introduces CKM syndrome stages, emphasizes social factors' impact on health, promotes collaborative care approaches, and suggests updates to the risk prediction algorithm for heart attack, stroke, and heart failure. #HeartDisease #CardiovascularHealth #Diabetes #KidneyDisease #CKMSyndrome #Healthcare #Prevention #RiskFactors #AmericanHeartAssociation
